Please login to the form below

Not currently logged in
Email:
Password:

Excellence in Customer Focus - Physician/Prescribing

Sponsored by

Finalist

Small Steps to Change to implement Treat to Target in rheumatoid arthritis – 2011

Abbott Laboratories in association with DNA Medical Communications


Summary of work

The Treat to Target concept in rheumatoid arthritis was developed by an International Committee and centres on early referral, diagnosis and regular assessment to make disease remission a realistic target for patients. The UK rolled-out the Treat to Target principles and recommendations nationally through a revolutionary programme, Small Steps to Change (SSTC), enabling rheumatologists to break change into small steps, through low-/no-cost solutions delivering target-driven regimens (Treat to Target). Partnership with the most influential UK KOLs (including the 2011 European Rheumatology Professional Body [EULAR] chair) led to the inclusion of Treat to Target in the latest SIGN guidance and publication of a consensus on standardising assessment using DAS28 in a peer-reviewed journal. SSTC changed routine practice in over 40 UK units with huge improvements in referral rates (10.76 to two weeks), assessment completion rates (16.7 per cent to 78.9-100 per cent) and fewer patients with high disease activity at referral (40 per cent vs 25 per cent).

 

 

Executive summary as submitted

Judges comments

"Abbott effectively tackled the ‘dual specialty’ conflict, which sometimes sees patients ignored by both specialties, in a simple way. It also identified 100 people in just one centre that would not have been diagnosed were it not for this campaign."